- The first practical introduction to second-order and growth mixture models using Mplus 8.4 -Introduces simple and complex models through incremental steps with increasing complexity -Each model is presented with figures with associated syntax that highlight what the statistics mean, Mplus applications, and an interpretation of results, to maximize understanding. - Second-order and growth mixture modeling is increasingly being used in various disciplines to analyze changes in individual attributes such as personal behaviors and relationships over time

A thorough treatment of the statistical methods used to analyze doubly truncated data In The Statistical Analysis of Doubly Truncated Data, an expert team of statisticians delivers an up-to-date review of existing methods used to deal with randomly truncated data, with a focus on the challenging problem of random double truncation. The authors comprehensively introduce doubly truncated data before moving on to discussions of the latest developments in the field. The book offers readers examples with R code along with real data from astronomy, engineering, and the biomedical sciences to illustrate and highlight the methods described within. Linear regression models for doubly truncated responses are provided and the influence of the bandwidth in the performance of kernel-type estimators, as well as guidelines for the selection of the smoothing parameter, are explored. Fully nonparametric and semiparametric estimators are explored and illustrated with real data. R code for reproducing the data examples is also provided. The book also offers: A thorough introduction to the existing methods that deal with randomly truncated data Comprehensive explorations of linear regression models for doubly truncated responses Practical discussions of the influence of bandwidth in the performance of kernel-type estimators and guidelines for the selection of the smoothing parameter In-depth examinations of nonparametric and semiparametric estimators Perfect for statistical professionals with some background in mathematical statistics, biostatisticians, and mathematicians with an interest in survival analysis and epidemiology, The Statistical Analysis of Doubly Truncated Data is also an invaluable addition to the libraries of biomedical scientists and practitioners, as well as postgraduate students studying survival analysis.

It is common practice to evaluate wastewater to understand drug consumption, from antibiotics to illegal narcotics, and even to analyze dietary habits and trends. Evaluating contaminants in wastewater enables researchers, environmental scientists, and water quality experts to gain valuable information and data. Wastewater-based epidemiology is an emerging science that has proven to be a cost- and time-effective biomonitoring tool. This book provides a roadmap for detecting wastewater-borne pathogenic contaminants such as viruses, bacteria, fungi, and others. It provides a basic, fundamental discussion of how sampling and monitoring of wastewater using epidemiological concepts and practices can aid in determining the presence of the COVID-19 virus in a community, for example, and may help predict future outbreaks. Features * Offers a unique discussion of the detection of bacteria, fungi, and COVID-19, and other viruses in wastewater * Presents the fundamentals of wastewater chemistry and microbiology * Explains biomonitoring, sampling, testing, and health surveillance in a practical manner Fundamentals of Wastewater-Based Epidemiology: Biomonitoring of Bacteria, Fungi, COVID-19, and Other Viruses is an invaluable resource to a wide array of readers with varying interests and backgrounds in water science and public health.

Statistical concepts provide scientific framework in experimental studies, including randomized controlled trials. In order to design, monitor, analyze and draw conclusions scientifically from such clinical trials, clinical investigators and statisticians should have a firm grasp of the requisite statistical concepts. The Handbook of Statistical Methods for Randomized Controlled Trials presents these statistical concepts in a logical sequence from beginning to end and can be used as a textbook in a course or as a reference on statistical methods for randomized controlled trials. Part I provides a brief historical background on modern randomized controlled trials and introduces statistical concepts central to planning, monitoring and analysis of randomized controlled trials. Part II describes statistical methods for analysis of different types of outcomes and the associated statistical distributions used in testing the statistical hypotheses regarding the clinical questions. Part III describes some of the most used experimental designs for randomized controlled trials including the sample size estimation necessary in planning. Part IV describe statistical methods used in interim analysis for monitoring of efficacy and safety data. Part V describe important issues in statistical analyses such as multiple testing, subgroup analysis, competing risks and joint models for longitudinal markers and clinical outcomes. Part VI addresses selected miscellaneous topics in design and analysis including multiple assignment randomization trials, analysis of safety outcomes, non-inferiority trials, incorporating historical data, and validation of surrogate outcomes.

Progressively more and more attention has been paid to how location affects health outcomes. The area of disease mapping focusses on these problems, and the Bayesian paradigm has a major role to play in the understanding of the complex interplay of context and individual predisposition in such studies of disease. Using R for Bayesian Spatial and Spatio-Temporal Health Modeling provides a major resource for those interested in applying Bayesian methodology in small area health data studies. Features: Review of R graphics relevant to spatial health data Overview of Bayesian methods and Bayesian hierarchical modeling as applied to spatial data Bayesian Computation and goodness-of-fit Review of basic Bayesian disease mapping models Spatio-temporal modeling with MCMC and INLA Special topics include multivariate models, survival analysis, missing data, measurement error, variable selection, individual event modeling, and infectious disease modeling Software for fitting models based on BRugs, Nimble, CARBayes and INLA Provides code relevant to fitting all examples throughout the book at a supplementary website The book fills a void in the literature and available software, providing a crucial link for students and professionals alike to engage in the analysis of spatial and spatio-temporal health data from a Bayesian perspective using R. The book emphasizes the use of MCMC via Nimble, BRugs, and CARBAyes, but also includes INLA for comparative purposes. In addition, a wide range of packages useful in the analysis of geo-referenced spatial data are employed and code is provided. It will likely become a key reference for researchers and students from biostatistics, epidemiology, public health, and environmental science.

Identifying the existing challenges and shortfalls of China's current HIV/AIDS programming, this book provides an understanding of the history of HIV/AIDS in China, comparing government responses to global best practice in prevention and treatment. Considering three key populations in China, namely, female sex workers, people who inject drugs and floating migrants, Living in the Shadows of China's HIV/AIDS Epidemics highlights the effects of high mobility and marginalisation on the spread of HIV in China. It is argued that these groups often suffer from stigmatisation and a lack of human security, resulting in sub-optimal outcomes for HIV/AIDS intervention and prevention efforts and the reinforcement of high-risk behaviours, further contributing to the transmission of the virus to the general population. In adding to the emerging body of literature, this book further elucidates the myriad of challenges posed by HIV/AIDS epidemics, allowing sustained engagement and a fresh insight into how governments might respond to the needs of individuals living with HIV/AIDS, both in China and globally. Including case studies which give voice to research participants in a rich and engaging way, this book will appeal to students and scholars of Chinese Studies, Asian Studies, International Relations and Political Science, as well as those engaged in epidemiological studies in the Health Sciences.

Published in 1986: This book tells the story of how various persons and groups have successfully dealt with a type of problem which may threaten the lives and health of every group of humans - every community. The problem is that of a polluted environment.

The integrated nested Laplace approximation (INLA) is a recent computational method that can fit Bayesian models in a fraction of the time required by typical Markov chain Monte Carlo (MCMC) methods. INLA focuses on marginal inference on the model parameters of latent Gaussian Markov random fields models and exploits conditional independence properties in the model for computational speed. Bayesian Inference with INLA provides a description of INLA and its associated R package for model fitting. This book describes the underlying methodology as well as how to fit a wide range of models with R. Topics covered include generalized linear mixed-effects models, multilevel models, spatial and spatio-temporal models, smoothing methods, survival analysis, imputation of missing values, and mixture models. Advanced features of the INLA package and how to extend the number of priors and latent models available in the package are discussed. All examples in the book are fully reproducible and datasets and R code are available from the book website. This book will be helpful to researchers from different areas with some background in Bayesian inference that want to apply the INLA method in their work. The examples cover topics on biostatistics, econometrics, education, environmental science, epidemiology, public health, and the social sciences.

Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.

Mathematical and Statistical Skills in the Biopharmaceutical Industry: A Pragmatic Approach describes a philosophy of efficient problem solving showcased using examples pertinent to the biostatistics function in clinical drug development. It was written to share a quintessence of the authors' experiences acquired during many years of relevant work in the biopharmaceutical industry. The book will be useful will be useful for biopharmaceutical industry statisticians at different seniority levels and for graduate students who consider a biostatistics-related career in this industry. Features: Describes a system of principles for pragmatic problem solving in clinical drug development. Discusses differences in the work of a biostatistician in small pharma and big pharma. Explains the importance/relevance of statistical programming and data management for biostatistics and necessity for integration on various levels. Describes some useful statistical background that can be capitalized upon in the drug development enterprise. Explains some hot topics and current trends in biostatistics in simple, non-technical terms. Discusses incompleteness of any system of standard operating procedures, rules and regulations. Provides a classification of scoring systems and proposes a novel approach for evaluation of the safety outcome for a completed randomized clinical trial. Presents applications of the problem solving philosophy in a highly problematic transfusion field where many investigational compounds have failed. Discusses realistic planning of open-ended projects.

Since the publication of the second edition, many new Bayesian tools and methods have been developed for space-time data analysis, the predictive modeling of health outcomes, and other spatial biostatistical areas. Exploring these new developments, Bayesian Disease Mapping: Hierarchical Modeling in Spatial Epidemiology, Third Edition provides an up-to-date, cohesive account of the full range of Bayesian disease mapping methods and applications. In addition to the new material, the book also covers more conventional areas such as relative risk estimation, clustering, spatial survival analysis, and longitudinal analysis. After an introduction to Bayesian inference, computation, and model assessment, the text focuses on important themes, including disease map reconstruction, cluster detection, regression and ecological analysis, putative hazard modeling, analysis of multiple scales and multiple diseases, spatial survival and longitudinal studies, spatiotemporal methods, and map surveillance. It shows how Bayesian disease mapping can yield significant insights into georeferenced health data. The target audience for this text is public health specialists, epidemiologists, and biostatisticians who need to work with geo-referenced health data.

This book demonstrates that a pandemic of coronary heart disease occurred in North America, western and northern Europe, and Australia and New Zealand from the 1930s to about 2000. At its peak it caused more deaths than any other disease. The book examines and compares trends in coronary heart disease mortality rates for individual countries. The most detailed analyses are for the United States, where mortality rates are examined for race, sex, and age groups and for geographic regions. Popular explanations for the rise and fall of coronary heart disease mortality rates are examined.

Maintaining a practical perspective, Bioequivalence and Statistics in Clinical Pharmacology, Second Edition explores statistics used in day-to-day clinical pharmacology work. The book is a starting point for those involved in such research and covers the methods needed to design, analyze, and interpret bioequivalence trials; explores when, how, and why these studies are performed as part of drug development; and demonstrates the methods using real world examples. Drawing on knowledge gained directly from working in the pharmaceutical industry, the authors set the stage by describing the general role of statistics. Once the foundation of clinical pharmacology drug development, regulatory applications, and the design and analysis of bioequivalence trials are established, including recent regulatory changes in design and analysis and in particular sample-size adaptation, they move on to related topics in clinical pharmacology involving the use of cross-over designs. These include, but are not limited to, safety studies in Phase I, dose-response trials, drug interaction trials, food-effect and combination trials, QTc and other pharmacodynamic equivalence trials, proof-of-concept trials, dose-proportionality trials, and vaccines trials. This second edition addresses several recent developments in the field, including new chapters on adaptive bioequivalence studies, scaled average bioequivalence testing, and vaccine trials. Purposefully designed to be instantly applicable, Bioequivalence and Statistics in Clinical Pharmacology, Second Edition provides examples of SAS and R code so that the analyses described can be immediately implemented. The authors have made extensive use of the proc mixed procedures available in SAS.

This book provides practical knowledge to clinicians and biomedical researchers using biological and biochemical specimen/samples in order to understand health and disease processes at cellular, clinical, and population levels. Concepts and techniques provided will help researchers design and conduct studies, then translate data from bench to clinics in attempt to improve the health of patients and populations. This book presents the extreme complexity of epidemiologic research in a concise manner that will address the issue of confounders, thus allowing for more valid inferences and yielding results that are more reliable and accurate.

First published in 1889, this book provides a guide to vital statistics- the science of numbers applied to the life-history of communities and nations- in relation to medical problems. Chapters cover a wide variety of categories including population, births and deaths, sickness, occupation and mortality, and mortality from special diseases.

Single-Arm Phase II Survival Trial Design provides a comprehensive summary to the most commonly- used methods for single-arm phase II trial design with time-to-event endpoints. Single-arm phase II trials are a key component for successfully developing advanced cancer drugs and treatments, particular for target therapy and immunotherapy in which time-to-event endpoints are often the primary endpoints. Most test statistics for single-arm phase II trial design with time-to-event endpoints are not available in commercial software. Key Features: Covers the most frequently used methods for single-arm phase II trial design with time-to-event endpoints in a comprehensive fashion. Provides new material on phase II immunotherapy trial design and phase II trial design with TTP ratio endpoint. Illustrates trial designs by real clinical trial examples Includes R code for all methods proposed in the book, enabling straightforward sample size calculation.

Contemporary research on genetic control of disease-transmitting insects knows two kinds of scientists: those that work in the laboratory and those known as a ~field peoplea (TM). Over the last decade, both groups seem to have developed differing research priorities, addressed fundamentally different aspects within the overall discipline of infectious-disease control, and worse, have developed a scientific a ~languagea (TM) that is no longer understood by the a ~othera (TM) party. This gap widens every day, between the North and the South, between ecologists and molecular biologists, geneticists and behaviourists, etc. The need to develop a common research agenda that bridges this gap has been identified as a top priority by all parties involved. Only then shall the goal of developing appropriate genetic-control strategies for vectors of disease become reality.

This book is the reflection of a workshop, held in Nairobi (Kenya) in July 2004, that addressed the above issues. It brought together a good representation of both the molecular and ecological research disciplines and, for the first time, included a significant number of researchers from disease-endemic countries. The research agenda presented here will serve the research and science-policy communities alike, and guide sponsoring organizations with the selection of priority areas for research funding.

This book is about building platforms for pandemic prediction. It provides an overview of probabilistic prediction for pandemic modeling based on a data-driven approach. It also provides guidance on building platforms with currently available technology using tools such as R, Shiny, and interactive plotting programs. The focus is on the integration of statistics and computing tools rather than on an in-depth analysis of all possibilities on each side. Readers can follow different reading paths through the book, depending on their needs. The book is meant as a basis for further investigation of statistical modelling, implementation tools, monitoring aspects, and software functionalities. Features: A general but parsimonious class of models to perform statistical prediction for epidemics, using a Bayesian approach Implementation of automated routines to obtain daily prediction results How to interactively visualize the model results Strategies for monitoring the performance of the predictions and identifying potential issues in the results Discusses the many decisions required to develop and publish online platforms Supplemented by an R package and its specific functionalities to model epidemic outbreaks The book is geared towards practitioners with an interest in the development and presentation of results in an online platform of statistical analysis of epidemiological data. The primary audience includes applied statisticians, biostatisticians, computer scientists, epidemiologists, and professionals interested in learning more about epidemic modelling in general, including the COVID-19 pandemic, and platform building. The authors are professors at the Statistics Department at Universidade Federal de Minas Gerais. Their research records exhibit contributions applied to a number of areas of Science, including Epidemiology. Their research activities include books published with Chapman and Hall/CRC and papers in high quality journals. They have also been involved with academic management of graduate programs in Statistics and one of them is currently the President of the Brazilian Statistical Association.

This book is about building platforms for pandemic prediction. It provides an overview of probabilistic prediction for pandemic modeling based on a data-driven approach. It also provides guidance on building platforms with currently available technology using tools such as R, Shiny, and interactive plotting programs. The focus is on the integration of statistics and computing tools rather than on an in-depth analysis of all possibilities on each side. Readers can follow different reading paths through the book, depending on their needs. The book is meant as a basis for further investigation of statistical modelling, implementation tools, monitoring aspects, and software functionalities. Features: A general but parsimonious class of models to perform statistical prediction for epidemics, using a Bayesian approach Implementation of automated routines to obtain daily prediction results How to interactively visualize the model results Strategies for monitoring the performance of the predictions and identifying potential issues in the results Discusses the many decisions required to develop and publish online platforms Supplemented by an R package and its specific functionalities to model epidemic outbreaks The book is geared towards practitioners with an interest in the development and presentation of results in an online platform of statistical analysis of epidemiological data. The primary audience includes applied statisticians, biostatisticians, computer scientists, epidemiologists, and professionals interested in learning more about epidemic modelling in general, including the COVID-19 pandemic, and platform building. The authors are professors at the Statistics Department at Universidade Federal de Minas Gerais. Their research records exhibit contributions applied to a number of areas of Science, including Epidemiology. Their research activities include books published with Chapman and Hall/CRC and papers in high quality journals. They have also been involved with academic management of graduate programs in Statistics and one of them is currently the President of the Brazilian Statistical Association.

The term health technology refers to drugs, devices, and programs that can improve and extend quality of life. As decision-makers struggle to find ways to reduce costs while improving health care delivery, health technology assessments (HTA) provide the evidence required to make better-informed decisions. This is the first book that focuses on the statistical options of HTAs, to fully capture the value of health improvements along with their associated economic consequences. After reading the book, readers will better understand why some health technologies receive regulatory or reimbursement approval while others do not, what can be done to improve the chances of approval, as well as common shortcomings of submissions for drug and device reimbursement. The book begins by contrasting the differences between regulatory approval and reimbursement approval. Next, it reviews the principles and steps for conducting an HTA, including the reasons why different agencies will have a different focus for their scope in the HTA. Supplying an accessible introduction to the various statistical options for different methods in an HTA, the book identifies the links to regulatory and reimbursement decisions for each option. It highlights many of the methodological advances that have occurred since HTA research began, to provide researchers and decision-makers with a cutting-edge framework. It also details the logical basis for the methods along with simple instructions on how to conduct the various techniques. Both authors have considerable experience in generating evidence for submissions and reviewing submissions to decision-makers for funding. One of the authors has also received a nationally recognized lifetime achievement award in this area.

With ever-rising healthcare costs, evidence generation through Health Economics and Outcomes Research (HEOR) plays an increasingly important role in decision-making about the allocation of resources. Accordingly, it is now customary for health technology assessment and reimbursement agencies to request for HEOR evidence, in addition to data from clinical trials, to inform decisions about patient access to new treatment options. While there is a great deal of literature on HEOR, there is a need for a volume that presents a coherent and unified review of the major issues that arise in application, especially from a statistical perspective. Statistical Topics in Health Economics and Outcomes Research fulfils that need by presenting an overview of the key analytical issues and best practice. Special attention is paid to key assumptions and other salient features of statistical methods customarily used in the area, and appropriate and relatively comprehensive references are made to emerging trends. The content of the book is purposefully designed to be accessible to readers with basic quantitative backgrounds, while providing an in-depth coverage of relatively complex statistical issues. The book will make a very useful reference for researchers in the pharmaceutical industry, academia, and research institutions involved with HEOR studies. The targeted readers may include statisticians, data scientists, epidemiologists, outcomes researchers, health economists, and healthcare policy and decision-makers.

This volume provides an overview of recent advances in our understanding of the biology of marburg- and ebolaviruses. It focuses on four essential areas: 1) ecology, outbreaks and clinical management, 2) disease, pathogenesis and protection, 3) virus replication inside the cell, and 4) molecular tools for virus study and taxonomy. For 50 years, these viruses have spilled over sporadically and without warning from their wildlife reservoirs, often causing major outbreaks and high fatalities. The consequences can be devastating, with a clear potential for global reach, as demonstrated by the 2013 West African outbreak of Ebola virus, which led to over 28,000 reported cases across three continents and more than 11,000 deaths. Given the international threat posed by these viruses, the pace and scope of basic research have also greatly intensified, ranging from studies of virus emergence, epidemiology, antiviral countermeasures and human disease to detailed mechanistic studies of virus entry, replication, virion assembly and protein structure. Written by internationally respected experts, this book will appeal to a wide audience and be a valuable resource for basic researchers, clinicians and advanced students alike.

New public health governance arrangements under the coalition government have wide reaching implications for the delivery of health inequality interventions. Through the framework of understanding health inequalities as a 'wicked problem' the book develops an applied approach to researching, understanding and addressing these by drawing on complexity theory. Case studies illuminate the text, illustrating and discussing the issues in real life terms and enabling public health, health promotion and health policy students at postgraduate level to fully understand and address the complexities of health inequalities. The book is a valuable resource on current UK public health practice for academics, researchers and public health practitioners.

Structural equation modeling (SEM) is a very general and flexible multivariate technique that allows relationships among variables to be examined. The roots of SEM are in the social sciences. In writing this textbook, the authors look to make SEM accessible to a wider audience of researchers across many disciplines, addressing issues unique to health and medicine. SEM is often used in practice to model and test hypothesized causal relationships among observed and latent (unobserved) variables, including in analysis across time and groups. It can be viewed as the merging of a conceptual model, path diagram, confirmatory factor analysis, and path analysis. In this textbook the authors also discuss techniques, such as mixture modeling, that expand the capacity of SEM using a combination of both continuous and categorical latent variables. Features: Basic, intermediate, and advanced SEM topics Detailed applications, particularly relevant for health and medical scientists Topics and examples that are pertinent to both new and experienced SEM researchers Substantive issues in health and medicine in the context of SEM Both methodological and applied examples Numerous figures and diagrams to illustrate the examples As SEM experts situated among clinicians and multidisciplinary researchers in medical settings, the authors provide a broad, current, on the ground understanding of the issues faced by clinical and health services researchers and decision scientists. This book gives health and medical researchers the tools to apply SEM approaches to study complex relationships between clinical measurements, individual and community-level characteristics, and patient-reported scales.

This book is open access under a CC BY-NC-ND 4.0 license. This open access book is the first compilation that reviews a wide range of social determinants of health (SDHs) for non-communicable diseases (NCDs) and healthy ageing in Japan. With the highest life expectancy and the largest elderly population in the world, Japan has witnessed health inequality by region and social class becoming more prevalent since the 2000s. The first half of this volume describes in detail major NCDs, such as cancers, heart and kidney diseases, diabetes, stroke, and metabolic syndrome. The second half, on the other hand, explores various SDHs relating to healthy ageing. All chapters review and focus on SDHs, particularly health inequality associated with socio-economic status and social capital, which are widely addressed in the field of social epidemiology. The book makes the argument that "Health for All" advocated by the WHO should be implemented based on social justice and benefits for the greater society. Public health researchers and policymakers, both in Japan and other nations, will gain scientific evidence from this book to prepare for the coming era as ageing becomes a global issue.